• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二价铁制剂和三价铁制剂的生物利用度及治疗效果

Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations.

作者信息

Kaltwasser J P, Werner E, Niechzial M

出版信息

Arzneimittelforschung. 1987 Jan;37(1A):122-9.

PMID:3566867
Abstract

The bioavailability of iron on Fe(III)-hydroxide-polymaltose complex was compared intraindividually with that of Fe (II)-ascorbate (iron absorption) and a Fe (II)-sulphate quick release preparation (haemoglobin regeneration test). The study was carried out in a population of 16 healthy male volunteers, phlebotomized in weekly intervals until development of an iron deficiency anaemia in order to establish a test population with only small variations of their individual body iron status. Intestinal iron absorption in fasting state as measured by 59Fe whole body retention and simultaneous estimation from plasma iron tolerance curves was low for the 59Fe (III)-complex (1.2 +/- 0.1% (means +/- SD] as compared to the 59Fe (II)-ascorbate (43.7 +/- 7.1% (means +/- SD]. Iron administration together with a test meal did not affect the absorption from the 59Fe (II)-ascorbate, whereas the 59Fe (III)-complex showed a significant increase in absorption (8.8 +/- 4.7% (means +/- SD]. Haemoglobin (Hb) regeneration after 100 mg of iron as Fe (III)-complex and Fe (II)-sulphate administered during 28 days with meals amounted to a mean of 0.68 +/- 0.2 g/l and 1.1 +/- 0.3 g/l (means +/- SD) of total daily Hb-increase and a net-Hb-increase of 0.31 +/- 0.37 g/l and 0.79 +/- 0.36 g/l (means +/- SD), respectively. There was also a small but significant rise in serum ferritin during the oral treatment in both treatment groups. The results of Hb-regeneration after treatment with the Fe (III)-complex were in the range which could be expected from the absorption measurements.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

将氢氧化铁-聚麦芽糖复合物中铁的生物利用度与抗坏血酸亚铁(铁吸收)和硫酸亚铁速释制剂(血红蛋白再生试验)在个体内进行了比较。该研究在16名健康男性志愿者群体中进行,每周进行一次静脉放血,直至出现缺铁性贫血,以便建立一个个体身体铁状态差异较小的测试群体。通过59Fe全身保留量以及从血浆铁耐受曲线同时估算,在禁食状态下,59Fe(III)复合物的肠道铁吸收较低(1.2±0.1%(均值±标准差)),而59Fe(II)-抗坏血酸为43.7±7.1%(均值±标准差)。与测试餐一起服用铁剂对59Fe(II)-抗坏血酸的吸收没有影响,而59Fe(III)复合物的吸收则显著增加(8.8±4.7%(均值±标准差))。在28天内随餐服用100 mg铁(以Fe(III)复合物和硫酸亚铁形式)后,血红蛋白(Hb)再生量分别为每日总Hb增加量平均0.68±0.2 g/l和1.1±0.3 g/l(均值±标准差),净Hb增加量分别为0.31±0.37 g/l和0.79±0.36 g/l(均值±标准差)。两个治疗组在口服治疗期间血清铁蛋白也有小幅但显著的升高。用Fe(III)复合物治疗后的Hb再生结果在吸收测量所预期的范围内。(摘要截断于250字)

相似文献

1
Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations.二价铁制剂和三价铁制剂的生物利用度及治疗效果
Arzneimittelforschung. 1987 Jan;37(1A):122-9.
2
Bioavailability of trivalent iron in oral iron preparations. Therapeutic efficacy and iron absorption from simple ferric compounds and high- or low-molecular weight ferric hydroxide-carbohydrate complexes.口服铁制剂中三价铁的生物利用度。简单铁化合物以及高分子量或低分子量氢氧化铁 - 碳水化合物复合物的治疗效果及铁吸收情况。
Arzneimittelforschung. 1975 Mar;25(3):420-6.
3
Bioavailability of iron from oral ferric polymaltose in humans.口服聚麦芽糖铁在人体中的生物利用度。
Arzneimittelforschung. 1994 Jun;44(6):743-8.
4
On the absorption of divalent and trivalent iron in living rats.关于活体大鼠中二价铁和三价铁的吸收
Arzneimittelforschung. 1984;34(11):1570-4.
5
Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man.人体对经中子活化的市售口服柠檬酸铁(III)和氢氧化铁(III)-聚麦芽糖复合物中59Fe的肠道吸收情况。
Arzneimittelforschung. 1987 Jan;37(1A):105-7.
6
Bioavailability of bi- and trivalent oral iron preparations. Investigations of iron absorption by postabsorption serum iron concentrations curves.二价和三价口服铁制剂的生物利用度。通过吸收后血清铁浓度曲线研究铁的吸收情况。
Arzneimittelforschung. 1987 Jan;37(1A):107-12.
7
[Comparison of bio-availability, antianaemic efficacy, tolerance and drug costs in oral iron(II) and iron(III) preparations (author's transl)].口服铁(II)和铁(III)制剂的生物利用度、抗贫血疗效、耐受性及药物成本比较(作者译)
Med Klin. 1979 Nov 30;74(48):1818-24.
8
[Oral iron therapy. Bioavailability and therapeutic effectiveness of ferrous iron in effervescent tablets in posthemorrhagic iron deficiency anemia].[口服铁剂治疗。泡腾片中亚铁在出血后缺铁性贫血中的生物利用度及治疗效果]
Dtsch Med Wochenschr. 1989 Aug 4;114(31-32):1188-95. doi: 10.1055/s-2008-1066738.
9
[Intestinal absorption from therapeutic iron doses (author's transl)].
Arzneimittelforschung. 1976;26(11):2093-100.
10
Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats.大鼠给予氢氧化铁-聚麦芽糖复合物后的铁代谢动力学
Arzneimittelforschung. 1984;34(11):1560-9.

引用本文的文献

1
Management of Anemia in Patients with Inflammatory Bowel Disease (IBD).炎症性肠病(IBD)患者贫血的管理
Curr Treat Options Gastroenterol. 2018 Mar;16(1):112-128. doi: 10.1007/s11938-018-0174-2.
2
Recovery from dietary iron deficiency anaemia in rats by the intake of microencapsulated ferric saccharate.大鼠通过摄入微囊化蔗糖铁从膳食缺铁性贫血中恢复。
J Food Sci Technol. 2017 Aug;54(9):2913-2918. doi: 10.1007/s13197-017-2729-y. Epub 2017 Jun 19.
3
Effect of a short course of iron polymaltose on acquisition of malarial parasitaemia in anaemic Indonesian schoolchildren: a randomized trial.
短期服用聚麦芽糖铁对印度尼西亚贫血学童疟原虫血症感染的影响:一项随机试验。
Malar J. 2017 Jan 28;16(1):50. doi: 10.1186/s12936-017-1691-5.
4
The pharmacokinetics and pharmacodynamics of iron preparations.铁制剂的药代动力学和药效学。
Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012.
5
Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview.用于治疗缺铁性贫血的口服亚铁制剂与高铁制剂:临床概述
ScientificWorldJournal. 2012;2012:846824. doi: 10.1100/2012/846824. Epub 2012 May 2.
6
Clinical pharmacokinetics of ferric natural protein in iron-deficient females.缺铁女性中铁的天然蛋白的临床药代动力学。
Clin Drug Investig. 1998;15(4):319-25. doi: 10.2165/00044011-199815040-00008.
7
Iron therapy for renal anemia: how much needed, how much harmful?肾性贫血的铁剂治疗:需要多少,危害几何?
Pediatr Nephrol. 2007 Apr;22(4):480-9. doi: 10.1007/s00467-006-0405-y. Epub 2007 Jan 6.
8
Clinical pharmacokinetics of iron preparations.铁制剂的临床药代动力学
Clin Pharmacokinet. 1989 Aug;17(2):69-89. doi: 10.2165/00003088-198917020-00002.